1199782-88-1Relevant articles and documents
Identification of N-acyl-N-indanyl-α-phenylglycinamides as selective TRPM8 antagonists designed to mitigate the risk of adverse effects
Kobayashi, Jun-ichi,Hirasawa, Hideaki,Fujimori, Yoshikazu,Nakanishi, Osamu,Kamada, Noboru,Ikeda, Tetsuya,Yamamoto, Akitoshi,Kanbe, Hiroki
, (2020/12/21)
Transient receptor potential melastatin 8 (TRPM8), a temperature-sensitive ion channel responsible for detecting cold, is an attractive molecular target for the treatment of pain and other disorders. We have previously discovered a selective TRPM8 antagon
[alpha]-substituted glycineamide derivative
-
Page/Page column 34, (2016/10/07)
The present invention provides: a novel [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; and a use of the [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof for medical purposes. The present invention provides a compound which has an inhibitory activity on TRPM8 and is represented by general formula (I) [wherein A1 represents a C6-10 aryl group or the like; A2 represents a C6-10 aryl group or the like; X represents CH or the like; Y represents -CR1R2- or the like; R1 and R2 independently represent a hydrogen atom or the like; R3 and R4 independently represent a halogen atom or the like; and n represents 1 or 2] or a pharmacologically acceptable salt thereof. The compound (I) according to the present invention can be used as a therapeutic or prophylactic agent for diseases or conditions associated with afferent nerve hyperexcitability or injury.